New Antiviral drug on the Horizon for SARS COV-2
Hi, its Dr. Jeffrey Mark, this week I’d like to share with you the news on Merck’s (in partnership with Ridgeback) investigational Oral Antiviral drug molnupiravir. It was announced that this oral medication reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo (or people that did not get the drug) …
New Antiviral drug on the Horizon for SARS COV-2 Read More »